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Summ a r y
The gray platelet syndrome is a hereditary, usually autosomal recessive bleeding 
disorder caused by a deficiency of alpha granules in platelets. We detected a non-
sense mutation in the gene encoding the transcription factor GFI1B (growth factor 
independent 1B) that causes autosomal dominant gray platelet syndrome. Both gray 
platelets and megakaryocytes had abnormal marker expression. In addition, the 
megakaryocytes had dysplastic features, and they were abnormally distributed in 
the bone marrow. The GFI1B mutant protein inhibited nonmutant GFI1B transcrip-
tional activity in a dominant-negative manner. Our studies show that GFI1B, in addi-
tion to being causally related to the gray platelet syndrome, is key to megakaryocyte 
and platelet development.
Platelets are formed through fragmentation of megakaryo-cytes that reside in the bone marrow.1,2 Platelet alpha granules, which are by far the most abundant platelet organelles, store proteins that stimulate plate-
let adhesiveness, hemostasis, and wound healing.3,4 The gray platelet syndrome is 
an inherited bleeding disorder characterized by defective production of alpha gran-
ules.5,6 Patients with this syndrome have reduced numbers of larger-than-normal 
platelets, and on light microscopy these platelets have a typical gray appearance 
caused by the lack of alpha granules. For a final diagnosis, the lack of alpha gran-
ules must be confirmed by means of electron microscopy.7 Clinically, patients with 
the gray platelet syndrome have bleeding tendencies with variable severity.8 Ad-
ditional features associated with this syndrome are bone marrow fibrosis and the 
capture of neutrophils within megakaryocytes in a process known as emperipolesis 
(the presence of an intact cell within the cytoplasm of another intact cell).6,8
It has been proposed that the alpha-granule deficiency in the gray platelet syn-
drome can be attributed to the failure of megakaryocytes to efficiently route en-
dogenous proteins into alpha granules, thereby hampering the maturation of these 
granules.9,10 Although the gray platelet syndrome is most often an autosomal re-
cessive disease, families with an autosomal dominant inheritance pattern have been 
described as well.6,11 Recently, biallelic NBEAL2 missense mutations have been 
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identified in an autosomal recessive form of the 
gray platelet syndrome.12-14 NBEAL2 localizes to 
the dense tubular system in platelets,12 but how 
NBEAL2 mutations contribute to defective alpha-
granule formation remains unknown. No genes 
have been implicated in autosomal dominant gray 
platelet syndrome. Here we report on the identi-
fication of a nonsense mutation in the transcrip-
tion-factor gene, growth factor independent 1B 
(GFI1B), in a family with autosomal dominant 
gray platelet syndrome. GFI1B and its paralog 
GFI1 function as transcriptional repressors and 
play fundamental roles during hematopoie-
sis.15-20 Both proteins contain a highly conserved 
C-terminal region that includes three zinc fin-
gers that are necessary for interaction with DNA 
and an identical N-terminal region through 
which epigenetic modifiers required to inhibit 
transcription are recruited.16,21-23 In addition, 
GFI1 and GFI1B interact directly with other 
transcription factors to coregulate gene expres-
sion during blood-cell development.15
Me thods
Study Family
We studied a large family with an autosomal 
dominant form of thrombopathic thrombocyto-
penia characterized by mild-to-severe bleeding 
complications, a diagnosis originally described 
in 1968.24 The thrombopathic disorder in this 
family consisted of a low platelet count, an in-
creased platelet size, and few alpha granules. An 
updated evaluation of affected family members 
according to the current disease classification 
allowed us to redefine the clinical diagnosis as 
the gray platelet syndrome (number 139090 in the 
Online Mendelian Inheritance in Man database).
The study was approved by the institutional 
review board of Radboud University Medical 
Center. Written informed consent was obtained 
from all family members who underwent evalu-
ation.
laboratory Analyses
The bleeding score was calculated, and morpho-
logic and immunohistochemical studies, electron 
microscopy, flow cytometry, GFI1B sequencing, 
and platelet-related analyses were performed ac-
cording to standard procedures (see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org). Measurements of plas-
ma glycocalicin (Cusabio) and megakaryocyte 
colony-forming assays (StemCell Technologies) 
were performed according to the manufacturers’ 
instructions. Linkage analysis based on genome-
wide single-nucleotide polymorphism array with 
the use of Linkage 24 DNA Analysis BeadChips 
(Illumina), GFI1 and GFI1B gene-reporter assays, 
the method of retroviral transduction, and pri-
mary cell cultures are described in the Supple-
mentary Appendix.
R esult s
clinical findings and laboratory Analyses
Morphologic analysis of blood smears from the 
six affected family members who were evaluated 
showed a ghostlike, gray appearance of enlarged 
platelets, in contrast to the normal platelets ob-
served in the two unaffected family members 
(Fig. 1A and 1B). Electron-microscopic analysis 
confirmed a marked reduction in the number of 
alpha granules (Fig. 1C, 1D, and 1E).
Affected family members had moderate-to-
Figure 1 (facing page). Characteristics of Autosomal 
Dominant Gray Platelet Syndrome.
May–Grünwald-Giemsa staining in Panel A shows 
 normal platelets (arrows) obtained from unaffected 
Family Member II.4. May–Grünwald-Giemsa staining in 
Panel B shows large gray platelets (arrows) obtained 
from affected Family Member II.2. Electron-microscopic 
analysis in Panel C shows a normal platelet with numer-
ous alpha granules (arrows) in a specimen obtained from 
unaffected Family Member II.4. Electron-micro scopic 
analysis shows gray platelets with few alpha granules, 
which are poorly developed (arrows), in a specimen 
obtained from Family Member III.2, and no alpha gran-
ules in a specimen obtained from Family Member II.2 
(Panels D and E, respectively). Panels F through I show 
abnormalities in a bone marrow–biopsy specimen ob-
tained from affected Family Member III.2. Laguesse 
staining in Panel F reveals stage I bone marrow fibro-
sis, consisting of a focal network of fine, dark-staining 
reticulin fibers that extend from the sinuses. Hematoxylin 
and eosin staining in Panel G shows megakaryocytes 
that are both larger and smaller than normal, with shapes 
that deviate from the normal round form (arrows). Some 
nuclei are irregular and hyperchromatic. Periodic acid–
Schiff staining in Panel H shows the capture of neu-
trophils (arrows) by megakaryocytes (emperipolesis). 
β3 integrin–CD61 staining in Panel I shows stretched 
megakaryocytes abnormally positioned in tandem 
along the sinuses (arrows).
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severe bleeding tendencies (Table S1 in the Sup-
plementary Appendix). In addition to reduced 
platelet counts, diminished platelet factor 4 and 
β-thromboglobulin levels were observed in 
platelets obtained from the affected family 
members (Table S1 in the Supplementary Ap-
pendix).
Histopathological Findings
Histopathological examination of a bone marrow 
biopsy specimen obtained from Family Member 
III.2 (Fig. 2A) showed stage I myelofibrosis (Fig. 
1F) and cellular marrow with an increased num-
ber of megakaryocytes that were pleomorphic in 
size and shape (Fig. 1G, and Fig. S1 in the 
Supplementary Appendix). Emperipolesis was 
frequently observed (Fig. 1H, and Fig. S1 in the 
Supplementary Appendix). Megakaryocytes were 
clustered along bone marrow sinuses and had 
stretched features (Fig. 1I, and Fig. S1 in the 
Supplementary Appendix).
Linkage and Sequence Analyses
To determine the disease-causing mutation, we 
first performed linkage analyses in 14 family 
members and identified a candidate locus on 
chromosome 9q34 with a maximum LOD score 
of 3.9 (Fig. S2 and S3 in the Supplementary 
Appendix). Within the linked region, we consid-
ered GFI1B to be an excellent candidate gene be-
cause it encodes a transcriptional repressor that 
has been implicated in megakaryopoiesis.17-19
Sequence analysis detected a nonsense muta-
tion in exon 6 (c.859C→T, p.Gln287*) of GFI1B 
that completely cosegregated with the gray plate-
let syndrome (Fig. 2A and 2B, and Fig. S4 and 
Table S2 in the Supplementary Appendix). The 
mutation introduces a premature stop codon that 
is predicted to lead to the formation of a trun-
cated protein (GFI1BTr) that lacks 44 carboxy-
terminal amino acids (Fig. 2B). Since premature 
stop codons can induce nonsense-mediated mes-
senger RNA (mRNA) decay, we determined 
whether mutated GFI1B was expressed at the 
mRNA level. Sequencing of complementary DNA 
generated from CD34+ progenitor cells obtained 
from two affected family members showed that 
mutated and nonmutated GFI1B transcripts were 
expressed, indicating that the mutated transcript 
is not targeted for decay (Fig. S4 in the Supple-
mentary Appendix).
Molecular and functional characterization 
of mutated GFI1B
GFI1B functions as a transcriptional repressor. 
The truncating mutation is located within zinc 
finger 5, which is required for DNA binding. This 
zinc finger is 100% identical between humans 
and rodents (rats and mice), and it is identical to 
zinc finger 5 of the paralog GFI1 (Fig. 2B).20 
Murine Gfi1 and Gfi1b bind the same DNA con-
sensus sequence, and Gfi1 zinc finger 5 directly 
interacts with the major groove of the DNA core 
sequence AATC through four amino acids.22 
Because the truncated protein GFI1BTr lacks all 
these DNA-interacting amino acids (Fig. 2B), we 
hypothesized that it would be unable to repress 
gene expression. To test this hypothesis, we in-
troduced the truncating mutation in a GFI1B ex-
pression vector and performed transcriptional 
Figure 2 (facing page). GFI1B Nonsense Mutation  
in the Gray Platelet Syndrome, Inhibiting the Function  
of Nonmutant GFI1B.
Panel A shows the pedigree of the family with the gray 
platelet syndrome. Squares denote male family mem-
bers, circles female family members, solid symbols 
affected family members, open symbols unaffected 
family members, and slashes deceased family members. 
Mutation status is indicated below the number of each 
family member, with −/− indicating the absence and 
+/− the presence of the GFI1B c.859C→T, p.Gln287* 
mutation. Panel B (top) shows that human GFI1B 
 (hGFI1B) contains an N-terminal Snail/Gfi-1 (SNAG) 
domain through which epigenetic modifiers are re-
cruited. At the C-terminal, GFI1B contains six zinc fin-
gers, of which three through five are essential for DNA 
binding. The GFI1B nonsense mutation (c.859C→T, 
p.Gln287*) is located in zinc finger 5 (arrow). The 
 resulting truncated protein, GFI1BTr, lacks four DNA-
interacting amino acids in zinc finger 5 (bottom, arrows). 
GFI1B zinc finger 5 is identical to zinc finger 5 of human, 
rat, and mouse GFI1 (h/r/mGFI1). Panel C shows that 
expression of GFI1 and GFI1B in HEK293T cells results 
in 60 to 75% repression of the reporter construct; GFI1BTr 
does not repress the reporter. In cotransfection experi-
ments, GFI1BTr inhibited the repression mediated by 
GFI1B. T bars represent standard errors. May–Grünwald-
Giemsa staining in Panel D shows abnormal megakaryo-
cytes (right) characterized by dysplastic features, in-
cluding hypolobulation of the nucleus and multiple 
separated nuclei. These abnormal megakaryocytes 
developed after retroviral expression of GFI1BTr in mu-
rine lineage c-kit–positive progenitor cells, followed by 
megakaryocytic differentiation. Megakaryocytes de-
rived from control vector–transduced bone marrow 
cells (left) had normal morphologic features.
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repression assays using the Gfi1 promoter as a 
validated Gfi1B target.25 In line with the lack of 
an intact DNA-binding zinc finger, we observed 
that GFI1BTr did not repress the Gfi1 promoter, 
whereas the nonmutant GFI1 and GFI1B did (Fig. 
2C, and Fig. S5 in the Supplementary Appendix). 
When coexpressed, GFI1BTr inhibited repression 
mediated by nonmutant GFI1B, indicating that 
the mutant interferes with nonmutant GFI1B in a 
dominant-negative fashion (Fig. 2C).
To validate that GFI1BTr adversely affects nor-
mal GFI1B, we expressed GFI1BTr in mouse bone 
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marrow cells and then induced megakaryocytic 
differentiation. GFI1BTr-positive megakaryocytes 
had several dysplastic features, including hypo-
lobulation of the nuclei, irregular contours, and 
multiple separated nuclei; these features were 
not observed in control cells (Fig. 2D, and Fig. 
S6 in the Supplementary Appendix). These ab-
normalities are very similar to those observed in 
cells obtained from affected family members 
with the gray platelet syndrome (Fig. 3E), indi-
cating that expression of GFI1BTr is sufficient to 
cause megakaryocytic abnormalities and that it 
functions in a dominant-negative manner.
cellular Analyses
Studies involving Gfi1b knockout mice have shown 
that Gfi1b plays an important role in the develop-
ment of several hematopoietic lineages.15,17,19 In 
humans, GFI1B is required for in vitro differen-
tiation of erythrocytic and megakaryocytic lin-
eages.18 We observed that megakaryocyte colony-
forming cells were significantly more frequent 
in a bone marrow specimen from affected fam-
ily members than in a specimen from a healthy 
person. In addition, the colonies from the af-
fected family member were larger than those 
from a healthy control (Fig. 3A, and Fig. S7 in 
the Sup plementary Appendix); this is in line 
with the increased number of megakaryocytes 
in the  biopsy specimen from affected Family 
Member III.2 (Fig. 1I).
To determine whether GFI1BTr was associated 
with other hematopoietic abnormalities, we per-
formed immunophenotypic analyses of periph-
eral-blood specimens obtained from eight family 
members and five healthy controls. Myeloid and 
erythroid lineages were unaffected (data not 
shown). The surface expression of characteristic 
platelet markers, such as β3 glycoprotein–CD36, 
αIIβ integrin–CD41, and β3 integrin–CD61, was 
also unperturbed in all tested persons. However, 
as compared with unaffected family members 
and healthy controls, five of six affected mem-
bers had a marked decrease in the level of plate-
let surface-membrane glycoprotein 1bα–CD42B 
within the αIIβ integrin–CD41 platelet compart-
ment (Fig. S8 in the Supplementary Appendix). 
In addition, strong expression of CD34, which is 
usually confined to immature hematopoietic 
progenitors, was detected on platelets from all 
affected family members in the study (Fig. 3B). 
Because platelets are derived from megakar yo-
cytes,1,2 we evaluated whether aberrant ex-
pression of surface molecules was also present 
on megakaryocytes. Immunostaining (with β3 
integrin–CD61) of a bone marrow–biopsy speci-
men obtained from affected Family Member III.2 
confirmed the presence of megakaryocytes that 
had high levels of CD34 expression (Fig. 3C). 
Electron-microscopic analysis of the same biopsy 
specimens showed megakaryocytes with few alpha 
granules, which were small, irregularly shaped, 
and centrally located; the megakaryocytes were 
characterized by an extensive peripheral cyto-
plasm with irregular proplatelets, largely de-
void of cell organelles (Fig. 3D, and Fig. S9 in 
the Supplementary Appendix). Con sistently, bone 
marrow smears obtained from the same patient 
(Patient III.2) and her mother (Patient II.2) 
showed dysplastic megakaryocytes that were 
pale, as a result of diminished alpha granules 
(Fig. 3E). To determine whether these abnor-
malities were intrinsic to the cell, we stimulated 
CD34+ cells obtained from affected Family Mem-
bers II.2 and III.2 to differentiate along the mega-
karyocytic lineage in culture. Megakaryocytic 
cells had dysplastic features such as those ob-
served in the bone marrow aspirates (Fig. 3E). 
In addition, altered expression of CD34 and glyco-
protein 1bα–CD42B was observed in megakaryo-
cytic cells that were positive for αIIβ integrin–
CD41 (Fig. S10 in the Supple mentary Appendix).
Discussion
The gray platelet syndrome is a hereditary bleed-
ing disorder characterized by platelets that lack 
alpha granules.5-10 Recently, mutations in NBEAL2 
have been shown to cause an autosomal recessive 
form of the gray platelet syndrome.12-14 We found 
that a mutation in GFI1B was causally related to 
autosomal dominant gray platelet syndrome.
In addition to large gray platelets that are 
almost devoid of alpha granules, other phe-
nomena associated with the gray platelet syn-
drome, such as thrombocytopenia, emperipolesis, 
mild myelofibrosis, and low expression of plate-
let factor 4, were observed in affected persons. 
However, we also found new features of the gray 
platelet syndrome such as megakaryocytes and 
platelets that were strongly positive for the stem-
cell and progenitor-cell marker CD34, and had a 
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Figure 3. GFI1BTr-Associated Platelet and Megakaryocyte Abnormalities.
Panel A (αIIβ integrin–CD41 staining) shows the results of a megakaryocyte colony-forming assay of bone marrow 
cells from Family Member III.2, as compared with normal bone marrow cells from a healthy control. The cells from 
affected Family Member III.2 developed into more and bigger colonies. CFU denotes colony-forming units, and GPS 
the gray platelet syndrome. The graph in Panel B shows that platelets obtained from affected Family Members II.2, 
II.3, II.6, II.8, II.10, and III.2, as compared with platelets obtained from unaffected Family Members II.4 and II.7 and 
healthy controls, had high levels of CD34 expression. MFI denotes mean fluorescence intensity. In Panel C, CD34 
staining of a bone marrow–biopsy specimen obtained from affected Family Member III.2 (left) shows a high level 
of CD34 expression on affected megakaryocytes. β3 integrin–CD61 staining of a subsequent section from the same 
biopsy specimen (right) was performed to confirm that the megakaryocytes were CD34-positive. In Panel D, an 
electron micrograph of a biopsy specimen obtained from Family Member III.2 shows a megakaryocyte containing a few 
poorly developed alpha granules (arrows). Panel E (May–Grünwald-Giemsa staining) shows a normal megakaryocyte 
(upper left) in a bone marrow aspirate obtained from a person without the gray platelet syndrome and megakaryocytes 
generated in an ex vivo culture (lower left), as compared with examples of pale dysplastic megakaryocytes in a bone 
marrow aspirate obtained from Family Member III.2 (upper middle and right) and ex vivo–generated megakaryocytes 
from Family Member II.2 and Family Member III.2 (lower middle and right, respectively), which are characterized by 
nuclear hypolobulation and pale cytoplasm.
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diminished expression of glycoprotein 1bα–
CD42B. Diminished glycoprotein 1bα–CD42B 
platelet expression may contribute to the patho-
genesis of the gray platelet syndrome, since 
glycoprotein 1bα–CD42B plays an important 
role in the initial adhesion of platelets to vascu-
lar subendothelium after injury. Low platelet 
expression of glycoprotein 1bα–CD42B may be 
related to the large platelets observed in af-
fected persons, since large platelets are present 
in the Bernard–Soulier syndrome, a bleeding 
disorder caused by GP1BA/CD42B mutations. In 
addition, and possibly consequential to aberrant 
marker expression, we observed that megakaryo-
cytes were abnormally distributed within the 
bone marrow, and they were frequently aligned in 
clusters along the sinuses in a stretched fashion. 
These features, in combination with the presence 
of morphologic and nuclear abnormalities in 
megakaryocytes, indicate that GFI1BTr affects the 
terminal maturation of megakaryocytes.
GFI1B silencing and Gfi1b ablation studies have 
shown that the protein is fundamental to the 
development of several blood-cell lineages.15,17-20 
In the affected members of the family we stud-
ied, the presence of GFI1BTr was associated with 
major abnormalities only in the megakaryocytic 
lineage. The mutation in the gray platelet syn-
drome introduces a stop codon that results in a 
truncated GFI1B protein. The deleted region in-
cludes four amino acids that directly interact 
with DNA. Indeed, GFI1BTr expression did not 
inhibit gene expression, but it inhibited the 
function of nonmutant GFI1B. This indicates 
that the gray platelet syndrome may be caused 
not by GFI1B haploinsufficiency but rather by 
dominant-negative inhibition of the nonmutant 
protein. Indeed, forced GFI1BTr expression in 
normal bone marrow cells resulted in severely 
dysplastic megakaryocytes that were similar to 
those observed in affected persons. These find-
ings are consistent with mouse models showing 
that only complete Gfi1b ablation disturbs in vitro 
development of megakaryocytes, whereas the loss 
of a single Gfi1b allele is not sufficient to yield a 
clear phenotype.17 GFI1BTr retains several core-
pressor and transcription factor–interacting do-
mains and may act in a dominant-negative man-
ner by quenching proteins that would normally 
cooperate with nonmutant GFI1B. The identifi-
cation of GFI1B target genes that may be dis-
turbed by GFI1BTr would provide relevant insight 
into the molecular pathways that are key for 
megakaryopoiesis and platelet production.
In summary, our data indicate that GFI1B is a 
causative gene in autosomal dominant gray plate-
let syndrome. The truncated GFI1B mutant acts 
in a dominant-negative manner over the nonmu-
tant protein and affects the normal develop-
ment of megakaryocytes and platelets, reflecting 
the pivotal role of GFI1B in governing normal 
megakaryopoiesis and platelet production.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank Dominique Duménil, Ph.D., for sharing a human 
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References
1. Kaushansky K. Historical review: 
megakaryopoiesis and thrombopoiesis. 
Blood 2008;111:981-6.
2. Junt T, Schulze H, Chen Z, et al. 
Dynamic visualization of thrombopoiesis 
within bone marrow. Science 2007;317: 
1767-70.
3. Rendu F, Brohard-Bohn B. The plate-
let release reaction: granules’ constituents, 
secretion and functions. Platelets 2001; 
12:261-73.
4. Maynard DM, Heijnen HF, Horne MK, 
White JG, Gahl WA. Proteomic analysis of 
platelet alpha-granules using mass spec-
trometry. J Thromb Haemost 2007;5:1945-
55.
5. Raccuglia G. Gray platelet syndrome: 
a variety of qualitative platelet disorder. 
Am J Med 1971;51:818-28.
6. Nurden AT, Nurden P. The gray plate-
let syndrome: clinical spectrum of the 
disease. Blood Rev 2007;21:21-36.
7. White JG. Ultrastructural studies of 
the gray platelet syndrome. Am J Pathol 
1979;95:445-62.
8. Gunay-Aygun M, Zivony-Elboum Y, 
Gumruk F, et al. Gray platelet syndrome: 
natural history of a large patient cohort 
and locus assignment to chromosome 3p. 
Blood 2010;116:4990-5001.
9. Weiss HJ, Witte LD, Kaplan KL, et al. 
Heterogeneity in storage pool deficiency: 
studies on granule-bound substances in 
18 patients including variants deficient 
in alpha-granules, platelet factor 4, beta-
thromboglobulin, and platelet-derived 
growth factor. Blood 1979;54:1296-319.
10. Breton-Gorius J, Vainchenker W, 
Nurden A, Levy-Toledano S, Caen J. 
Defective alpha-granule production in 
megakaryocytes from gray platelet syn-
drome: ultrastructural studies of bone 
marrow cells and megakaryocytes grow-
ing in culture from blood precursors. Am 
J Pathol 1981;102:10-9.
11. Mori K, Suzuki S, Sugai K. Electron 
microscopic and functional studies on 
platelets in gray platelet syndrome. Tohoku 
J Exp Med 1984;143:261-87.
12. Gunay-Aygun M, Falik-Zaccai TC, 
Vilboux T, et al. NBEAL2 is mutated in 
gray platelet syndrome and is required for 
biogenesis of platelet α-granules. Nat 
Genet 2011;43:732-4.
13. Kahr WH, Hinckley J, Li L, et al. 
Mutations in NBEAL2, encoding a BEACH 
protein, cause gray platelet syndrome. Nat 
Genet 2011;43:738-40.
14. Albers CA, Cvejic A, Favier R, et al. 
Exome sequencing identifies NBEAL2 as 
the causative gene for gray platelet syn-
drome. Nat Genet 2011;43:735-7.
15. van der Meer LT, Jansen JH, van der 
Reijden BA. Gfi1 and Gfi1b: key regula-
tors of hematopoiesis. Leukemia 2010;24: 
1834-43.
16. Zweidler-Mckay PA, Grimes HL, 
Flubacher MM, Tsichlis PN. Gfi-1 en-
codes a nuclear zinc finger protein that 
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
brief report
n engl j med 370;3 nejm.org january 16, 2014 253
binds DNA and functions as a transcrip-
tional repressor. Mol Cell Biol 1996;16: 
4024-34.
17. Saleque S, Cameron S, Orkin SH. The 
zinc-finger proto-oncogene Gfi-1b is es-
sential for development of the erythroid 
and megakaryocytic lineages. Genes Dev 
2002;16:301-6.
18. Randrianarison-Huetz V, Laurent B, 
Bardet V, Blobe GC, Huetz F, Duménil D. 
Gfi-1B controls human erythroid and 
megakaryocytic differentiation by regu-
lating TGF-beta signaling at the bipotent 
erythro-megakaryocytic progenitor stage. 
Blood 2010;115:2784-95.
19. Khandanpour C, Sharif-Askari E, 
Vassen L, et al. Evidence that growth fac-
tor independence 1b regulates dormancy 
and peripheral blood mobilization of he-
matopoietic stem cells. Blood 2010;116: 
5149-61.
20. Person RE, Li FQ, Duan Z, et al. 
Mutations in proto-oncogene GFI1 cause 
human neutropenia and target ELA2. Nat 
Genet 2003;34:308-12.
21. Vassen L, Fiolka K, Möröy T. Gfi1b 
alters histone methylation at target gene 
promoters and sites of gamma-satellite 
containing heterochromatin. EMBO J 2006; 
25:2409-19.
22. Lee S, Doddapaneni K, Hogue A, 
McGhee L, Meyers S, Wu Z. Solution struc-
ture of Gfi-1 zinc domain bound to con-
sensus DNA. J Mol Biol 2010;397:1055-66.
23. Saleque S, Kim J, Rooke HM, Orkin 
SH. Epigenetic regulation of hematopoi-
etic differentiation by Gfi-1 and Gfi-1b is 
mediated by the cofactors CoREST and 
LSD1. Mol Cell 2007;27:562-72.
24. Kurstjens R, Bolt C, Vossen M, Haanen 
C. Familial thrombopathic thrombocyto-
penia. Br J Haematol 1968;15:305-17.
25. Vassen L, Fiolka K, Mahlmann S, 
Möröy T. Direct transcriptional repres-
sion of the genes encoding the zinc-finger 
proteins Gfi1b and Gfi1 by Gfi1b. Nucleic 
Acids Res 2005;33:987-98.
Copyright © 2013 Massachusetts Medical Society.
Keel Lough, Achill Island, Co. Mayo, Ireland Charles Cowles, M.D.
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
